Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$580.41
Price+2.55%
$14.44
1Y
Price
Market Cap
$60.461b
Large
Price/Earnings 3y Avg5y Avg
14.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+45.1%
EBITDA Margin+37.9%
Net Profit Margin+26.3%
Free Cash Flow MarginRevenue
$14.214b
+0.1%
1y CAGR+5.4%
3y CAGR-2.0%
5y CAGREarnings
$4.459b
+1.0%
1y CAGR+1.3%
3y CAGR-10.6%
5y CAGREPS
$39.68
+3.5%
1y CAGR+1.6%
3y CAGR-10.5%
5y CAGRBook Value
$29.939b
$38.219b
Assets$8.280b
Liabilities$2.705b
DebtDebt to Assets
7.1%
0.5x
Debt to EBITDAFree Cash Flow
$3.845b
+4.9%
1y CAGR-4.1%
3y CAGR-11.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company